N-acetylcysteine reduces tumor necrosis factor-α release by alveolar macrophages of interstitial lung disease in vitro Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007
Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis Source: Eur Respir J 2003; 21: 421-428 Year: 2003
Resistance of BAL immune cells to apoptosis in interstitial lung diseases (ILD) with high local tumor necrosis factor-α (TNFα) levels as a possible consequence of common TNF receptor type 2 expression Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008
Pulmonary lesions in patients with inflammatory bowel disease – the baseline and under anti-tumor necrosis factor therapy. Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017
Radiographic changes in patients with tumor necrosis factor alpha inhibitor and immunomodulatory drug users: Four years follow up Source: International Congress 2016 – Mixed-up imaging of various chest diseases Year: 2016
The influence of sera from interstitial lung diseases (ILD) patients on human mononuclear cells (MNC) production of vascular endothelial growth factor (VEGF) Source: Eur Respir J 2004; 24: Suppl. 48, 553s Year: 2004
TNFα and INFγ inducing capacity of sera from interstitial lung diseases (ILD) patients in relation to its angiogenic activity Source: Eur Respir J 2001; 18: Suppl. 33, 410s Year: 2001
Human neutrophil peptides stimulate the production of TNF alpha by alveolar macrophages from patients with sarcoidosis Source: Annual Congress 2007 - Inflammatory cell biology Year: 2007
Down regulation of stromal cell-derived factor 1 (SDF-1/CXCL12) in lung tissue of patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007
Broncholaveolar lavage (BAL) lymphocytes from patients with interstitial lung diseases (ILD) produce hepatocyte growth factor (HGF) Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009
The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 542s Year: 2006
Tumor necrosis factor-α gene polymorphism and inflammatory process in cystic fibrosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 403s Year: 2005
Upregulation of pro-inflammatory cytokines in the intercostal muscles of COPD patients Source: Eur Respir J 2007; 30: 701-707 Year: 2007
Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease Source: Eur Respir J 2006 Oct 01;28(4):824-831 Year: 2006
Hepatocyte growth factor (HGF) expression in bronchoveolar lower (BAL) does not confirm its anti-fibrotic activity in interstitial lung diseases (ILD) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012
Vascular endothelial growth factor (VEGF) levels in induced sputum and plasma in asymptomatic and COPD smokers. Correlation with airway and systemic inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 652s Year: 2006
Increased intraalveolar level of soluble endothelial protein C receptor in patients with interstitial lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 319s Year: 2004
Association of the TNF gene promoter polymorphism with serum tumor necrosis factor-alpha levels in chronic obstructive pulmonary disease patients Source: Eur Respir J 2006; 28: Suppl. 50, 522s Year: 2006
Decreased VEGF concentration in lung tissue and vascular injury during ARDS Source: Eur Respir J 2005; 25: 139-146 Year: 2005
Increased binding activity of hypoxia inducible factor (HIF)-1α to vascular endothelial growth factor (VEGF) promoter region mediates enhanced vascular permeability in the lung of cystic fibrosis (CF) patients Source: Eur Respir J 2003; 22: Suppl. 45, 173s Year: 2003